Lead investigator, ASCENT breast cancer trials
Appears in 1 story
Chief of breast oncology, Dana-Farber Cancer Institute
Triple-negative breast cancer is aggressive and short on options. On June 24, 2026, the U.S. Food and Drug Administration cleared Gilead Sciences' Trodelvy as a first-line treatment, moving a drug once used only after other therapies failed to the front of the line. Six days earlier, the European Commission had done the same for patients in the EU who are ineligible for immunotherapy.
Updated Jun 25
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
